Randomized Controlled Trial of Intraocular Lens Orientation for Dysphotopsia
Saagar V Pamulapati1, Jordan M Saeed1, Nichole Pompey1
1From the University of Illinois College of Medicine, Rockford, Illinois, USA.
Purpose:
To evaluate whether orientation of the optic-haptic junction of an intraocular lens (IOL) during cataract surgery could decrease the incidence and/or severity of positive and negative dysphotopsia.
Design:
Prospective, randomized controlled trial.
Methods:
A total of 163 patients (326 eyes) in a private practice scheduled to have bilateral implantation of a Tecnis monofocal IOL (ZCB00) (Johnson & Johnson Vision) were randomly assigned to have the optic-haptic junction positioned vertically, horizontally, superonasally, or inferonasally. Patients with known visual field defects or best-corrected vision less than 20/80 were excluded. Patients were surveyed for positive and negative dysphotopsia symptoms at 1 week and 4-6 weeks after surgery. Patients were blinded to the orientation whereas researchers were not. Data were analyzed to compare the differences in positive and negative dysphotopsia incidence and severity.
Results:
IOL oriented vertically in 82 eyes (25.2%), horizontally in 72 eyes (22.1%), superonasally in 94 eyes (28.8%), and inferonasally in 78 eyes (23.9%). Significant differences were noted between orientations in incidence of negative dysphotopsia at 1 week postoperatively (P = .019) and 4-6 weeks postoperatively (P = .002). Patients in the superonasal group had the worst outcome at both time periods, and the horizontal group had the best outcome at 4-6 weeks. No differences were noted for positive dysphotopsia incidence or severity.
Conclusions:
The orientation of the optic-haptic junction of a monofocal IOL was significantly associated with incidence of negative dysphotopsia after surgery, with the horizontal orientation performing best at 4-6 weeks.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Glaucoma: Overview


